ClinicalTrials.gg
CompletedNCT06821724RCTUpdated Feb 12, 2025

Effect of Different Remineralizing Agents on White Spot Lesions Treatment in Children

An interventional study of Casein phosphopeptide-amorphous calcium phosphate and Casein phosphopeptide-amorphous calcium phosphate + fluoride in White Spot Lesion of Tooth, sponsored by National Research Centre, Egypt. Completed at 1 site in Egypt. Open to participants aged 10 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by National Research Centre, Egypt · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
10 Years to 14 Years
Sex
All
01

Study summary

One hundred children with white spot lesions on their teeth were divivided into 5 groups of different remineralizing agents to assess their effect on color change and remineralization

Read the detailed description

Children having at least one tooth clinically diagnosed by white spot lesion were randomly allocated to five groups.

Group one: No treatment was applied (negative control). Group two: Fluoride gel was applied for 5 minutes (positive control). Group three: Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) (MI paste) was applied for 5 minutes.

Group four: Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) + fluoride (MI paste plus) were applied for 5 minutes.

Group five: Nano hydroxyapatite paste (Apagard primo toothpaste) was be applied for 5 minutes.

All children involved in this study were instructed to brush their teeth under the supervision of the researcher before the application of the studied agent.

Each agent was applied to the labial surfaces of each tooth affected with white spot lesion for 5 minutes after cleaning and drying with a cotton roll using an applicator tip. After each application, children were instructed not to eat or drink for one hour. This application was be repeated in-office after one then after two weeks then after six weeks.

Participants received a sterilized pouch containing a sterile container with one of the pastes according to the study group for home application. The application of the paste was carried out under parental supervision and was asked to apply each of the pastes at home three times a day till the end of the study

02

Conditions studied

  • White Spot Lesion of Tooth

Keywords

  • White spots
  • Remineralization
  • Caries
  • Children
03

In context

Lead sponsor

National Research Centre, Egypt is the lead sponsor of 51 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of at least one tooth affected by white spot lesion.
  2. Good oral hygiene and regular tooth brushing at least twice daily.

Exclusion criteria

Exclusion Criteria:

  1. Unwillingness to be randomly assigned to 1 of the 3 treatment groups.
  2. Presence of abnormal oral, medical, or mental condition.
  3. Presence of any milk-related allergies.
  4. Presence of dentin caries or enamel hypoplasia on maxillary anterior teeth.
  5. Presence of periodontal pockets around maxillary anterior teeth.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • No intervention
    No treatment

    Negative control

  • Active comparator
    Fluoride gel

    Positive control

    Drug: Fluoride gel

  • Experimental
    Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) (MI paste)

    Intervention

    Drug: Casein phosphopeptide-amorphous calcium phosphate

  • Experimental
    Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) + fluoride (MI paste plus)

    Intervention

    Drug: Casein phosphopeptide-amorphous calcium phosphate + fluoride

  • Experimental
    Nano hydroxyapatite paste (Apagard primo toothpaste)

    Intervention

    Drug: Nano hydroxyapatite paste

Interventions

  • DrugCasein phosphopeptide-amorphous calcium phosphate

    Intervention

    Also known as: (CPP-ACP) (MI paste)

  • DrugCasein phosphopeptide-amorphous calcium phosphate + fluoride

    Intervention

    Also known as: (CPP-ACP) + (MI paste plus)

  • DrugNano hydroxyapatite paste

    Intervention

    Also known as: (Apagard primo toothpaste)

  • DrugFluoridesStudies of FluoridesFluorides pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Positive control

    Also known as: Active Comparator

06

What researchers measure

Primary outcomes

  1. Assessment of color change

    Color change assessmentof white spot lesions using "Easy-shade" device

    Time frame: before treatment, immediately after treatment, 2 weeks and 6 weeks after the onset of treatment

Secondary outcomes

  1. Remineralization assessment

    Remineralization assessment will be done using Laser fluorescence device "DIAGNOdent® (KaVo)".

    Time frame: before treatment, immediately after treatment, 2 weeks and 6 weeks after the onset of treatment

07

Study locations

1 site
  • National Research Centre
    Dokki, Giza 12622, Egypt
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Jan 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 12, 2025
StartActual
Dec 1, 2024
Primary completionActual
Jan 15, 2025
CompletionActual
Feb 1, 2025
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06821724
Lead sponsor
National Research Centre, Egypt
Responsible party
Mohamed Farouk Rashed (Researcher of Pediatric Dentistry, National Research Centre, Egypt) — Principal investigator
First posted
Feb 12, 2025
Start date
Dec 1, 2024
Primary completion
Jan 15, 2025
Completion
Feb 1, 2025
Last update
Feb 12, 2025

Study contacts

Mohamed F Rashed, Researcher
study director · National Research Centre, Egypt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion